14 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Mycobacterium tuberculosis ... infection (TB) ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Mycobacterium tuberculosis ... infection (TB) ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
• HIV: 2/3 pulmonary ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
• HIV: 2/3 pulmonary ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... HIV-infected persons with clinical ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... Multi-Drug Resistant Tuberculosis ... #MDRTB #management ... #regimens #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
HIV-AIDS Preventing Clinical ... and preventing clinical ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
noncompliance • Clinical ... initiation Clinical ... , pulmonary infiltrates ... lymphadenitis, pulmonary ... Differential #Diagnosis #Management
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Herpes Simplex Virus ... • Continue treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Infection (Diffuse Pulmonary ... • Use until clinical ... IDSA #Prevention #Treatment ... #infections #HIVAIDS ... #pharmacology